MYLAN Pharmaceuticals has
announced the US release of
Alfuzosin Hydrochloride Extendedrelease
tablets, which is a generic
version of benign prostatic
hyperplasia treatment Uroxatral.
Urotraxal tablets accounted for
US$241m in sales last year.The above article was sent to subscribers in Pharmacy Daily's issue from 15 Aug 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Aug 11
STRONG growth in Australia has helped MedAdvisor Solutions achieve robust results for FY24, with a revenue increase of 24.6% on the previous corresponding period to $122.1 million.
WESFARMERS has today reported strong growth in revenue across its Health division and its Australian Pharmaceutical Industries (API) subsidiary, despite a significant reduction in COVID-19 anti-viral product sales.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.